Key result
Microalbuminuria, detectable in almost 40% of patients with established hypertension, is a marker of renal damage and cardiovascular risk that can be reduced by ACE-inhibitors and ARBs.
Why the study?
Does the detection of microalbuminuria help stratify cardiovascular and renal risk, and do ACE-inhibitors or ARBs reduce it in hypertensive and diabetic patients?
Does the detection of microalbuminuria help stratify cardiovascular and renal risk, and do ACE-inhibitors or ARBs reduce it in hypertensive and diabetic patients?
Microalbuminuria is a simple and reproducible marker for stratifying cardiovascular and renal risk in hypertensive patients, guiding the use of targeted therapies like ACE-inhibitors and ARBs.
Answers are grounded in this paper and cite their sources.
Microalbuminuria screening may aid risk stratification in hypertension; leaves open need for dedicated outcome trials on ACEi/ARB reduction.
The capacity of microalbuminuria to predict an increased cardiovascular and renal risk is well established in diabetic patients, as well as in essential hypertensive patients and in general population. Detection of microalbuminuria could then be relevant to select specific therapeutic strategies for reducing or preventing cardiovascular events in patients with essential hypertension. Microalbuminuria is detectable in almost 40% of the population with established hypertension, particularly in those patients not controlled satisfactorily with medical therapy. Albuminuria may represent a marker of renal damage and cardiovascular risk in essential hypertension. Microalbuminuria seems to represent a simple and reproducible method to better define cardiovascular risk profile in the hypertensive patient and to stratify the prognosis in relation to renal and cardiovascular risk. ACE-inhibitors and more recently angiotensin II receptor antagonists seem to exhibit a more market capacity to reduce microalbuminuria in patients with essential hypertension or diabetes mellitus. Determination of this parameter in daily clinical practice could facilitate the stratification of risk as well as the choice of therapy in essential hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Segura et al. (2004) conducted a review in Essential hypertension and diabetes mellitus. Microalbuminuria was evaluated. Microalbuminuria, detectable in almost 40% of patients with established hypertension, is a marker of renal damage and cardiovascular risk that can be reduced by ACE-inhibitors and ARBs.
Synapse has enriched 10 related papers. Consider them for comparative context: